Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Opicapone in Healthy Elderly vs Young Males
NCT02092168Phase 1Completed
- Sponsor
- BIAL
- Start
- Oct 2008
- Primary completion
- Jan 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of opicapone in Parkinson's disease (PD) (2 arms), sponsored by BIAL. Primary endpoints: Maximum Plasma Concentration at Day 7, Time to Reach Cmax at Day 7 and 1 more. Started Oct 2008; status: completed.
02
Drugs
opicapone
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT02092168.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02092168.